Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

Ландшафт тестирования дефицита гомологичной рекомбинации (HRD): клинические применения и техническая валидация для рутинной диагностики
Jean‐Louis Merlin, Andréa Witz, Julie Dardare, Margaux Betz, Cassandra Michel, Marie Husson, Pauline Gilson, Alexandre Harlé, Marie Husson, Pauline Gilson
2025-02-21

BRCA mutation testingHRD testing methodologiesPARP inhibitors (PARPi)genomic scarshomologous recombination deficiency (HRD)
The use of poly(ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of BRCA-mutated cancers. Identifying patients exhibiting homologous recombination deficiency (HRD) has been proved useful to predict PARPi efficacy. However, obtaining HRD status remains an arduous task due to its evolution over the time. This causes HRD status to become obsolete when obtained from genomic scars, rendering PARPi ineffective for these patients. Only two HRD tests are currently FDA-approved, both based on genomic scars detection and BRCA mutations testing. Nevertheless, new technologies for obtaining an increasingly reliable HRD status continue to evolve. Application of these tests in clinical practice is an additional challenge due to the need for lower costs and shorter time to results delay.In this review, we describe the currently available methods for HRD testing, including the methodologies and corresponding tests for assessing HRD status, and discuss the clinical routine application of these tests and their technical validation.
1
Clinical implementation of HRD testing faces challenges of cost reduction and shorter turnaround times, requiring technical validation for routine diagnostics.
2
HRD status can evolve over time, making genomic-scar-based HRD assessments potentially obsolete and leading to ineffective PARPi treatment.
3
New technologies for more reliable HRD assessment are emerging, aiming to overcome limitations of genomic-scar-based tests.
4
Only two FDA-approved HRD tests exist, both relying on genomic scar detection and BRCA mutation testing.
5
PARP inhibitors (PARPi) revolutionized treatment of BRCA-mutated cancers and HRD identification predicts PARPi efficacy.

Methods and tests for assessing homologous recombination deficiency (HRD) status

Clinical applications, routine diagnostic implementation, and technical validation (performance, reliability, cost and turnaround time) of HRD testing methods

Publication Details
Publication Date
2025-02-21
Journal
Publisher
ISSN
Cited by
44
Access Type
Author Information
Authors
Jean‐Louis Merlin
Andréa Witz
Julie Dardare
Margaux Betz
Cassandra Michel
Marie Husson
Pauline Gilson
Alexandre Harlé
Marie Husson
Pauline Gilson
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%